Values First Advisors Inc. Boosts Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Values First Advisors Inc. grew its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 7.6% in the third quarter, Holdings Channel reports. The institutional investor owned 10,412 shares of the biopharmaceutical company’s stock after buying an additional 738 shares during the period. Values First Advisors Inc.’s holdings in Royalty Pharma were worth $295,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. PNC Financial Services Group Inc. lifted its position in Royalty Pharma by 98.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,947 shares of the biopharmaceutical company’s stock valued at $308,000 after purchasing an additional 5,438 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of Royalty Pharma by 4,335.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,750 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 2,688 shares in the last quarter. New Century Financial Group LLC acquired a new position in Royalty Pharma during the first quarter worth $1,091,000. Principal Financial Group Inc. grew its holdings in Royalty Pharma by 34.6% during the first quarter. Principal Financial Group Inc. now owns 31,485 shares of the biopharmaceutical company’s stock worth $956,000 after acquiring an additional 8,086 shares during the period. Finally, Capstone Investment Advisors LLC purchased a new position in Royalty Pharma in the first quarter worth $542,000. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on RPRX. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, September 17th. The Goldman Sachs Group boosted their price target on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Finally, Morgan Stanley raised their price objective on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research note on Thursday, July 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Royalty Pharma Stock Performance

Shares of RPRX opened at $27.28 on Friday. The company has a 50-day moving average of $28.03 and a two-hundred day moving average of $27.65. The stock has a market cap of $16.30 billion, a P/E ratio of 20.36, a PEG ratio of 4.03 and a beta of 0.46. Royalty Pharma plc has a 12-month low of $25.20 and a 12-month high of $31.66. The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.78.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.01. The firm had revenue of $537.00 million for the quarter, compared to analyst estimates of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same quarter in the prior year, the company earned $0.85 EPS. As a group, research analysts predict that Royalty Pharma plc will post 4.05 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date is Friday, November 15th. Royalty Pharma’s payout ratio is currently 62.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.